{"id":"https://openalex.org/W4389243050","doi":"https://doi.org/10.1182/blood-2023-179577","title":"A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)","display_name":"A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)","publication_year":2023,"publication_date":"2023-11-02","ids":{"openalex":"https://openalex.org/W4389243050","doi":"https://doi.org/10.1182/blood-2023-179577"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2023-179577","doi":"https://doi.org/10.1182/blood-2023-179577","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2023-179577","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew S Davids","raw_affiliation_strings":["1Department of Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036627133","display_name":"Yesid Alvarado Valero","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yesid Alvarado Valero","raw_affiliation_strings":["2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014995908","display_name":"Catherine Diefenbach","orcid":"https://orcid.org/0000-0003-1116-3246","observed_orcids":["https://orcid.org/0000-0003-1116-3246"]},"institutions":[{"id":"https://openalex.org/I4210086933","display_name":"NYU Langone Health","ror":"https://ror.org/005dvqh91","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210086933"]},{"id":"https://openalex.org/I57206974","display_name":"New York University","ror":"https://ror.org/0190ak572","country_code":"US","type":"education","lineage":["https://openalex.org/I57206974"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Catherine Diefenbach","raw_affiliation_strings":["3NYU School of Medicine, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3NYU School of Medicine, New York, NY","institution_ids":["https://openalex.org/I4210086933","https://openalex.org/I57206974"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033698142","display_name":"Daniel N. Egan","orcid":"https://orcid.org/0000-0002-0523-1188","observed_orcids":["https://orcid.org/0000-0002-0523-1188","https://orcid.org/0000-0002-0173-5194"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel N. Egan","raw_affiliation_strings":["4Swedish Center for Blood Disorders and Stem Cell Transplants, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Swedish Center for Blood Disorders and Stem Cell Transplants, Seattle, WA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066185867","display_name":"Shira Naomi Dinner","orcid":"https://orcid.org/0000-0002-3635-6741","observed_orcids":["https://orcid.org/0000-0002-3635-6741"]},"institutions":[{"id":"https://openalex.org/I111979921","display_name":"Northwestern University","ror":"https://ror.org/000e0be47","country_code":"US","type":"education","lineage":["https://openalex.org/I111979921"]},{"id":"https://openalex.org/I4390039227","display_name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","ror":"https://ror.org/02p4far57","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I4210147348","https://openalex.org/I4390039227"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shira N. Dinner","raw_affiliation_strings":["5Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL","institution_ids":["https://openalex.org/I111979921","https://openalex.org/I4390039227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048360588","display_name":"Monzr M. Al Malki","orcid":"https://orcid.org/0000-0001-8226-471X","observed_orcids":["https://orcid.org/0000-0001-8226-471X"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]},{"id":"https://openalex.org/I4210110459","display_name":"City of Hope","ror":"https://ror.org/01z1vct10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Monzr M. Al Malki","raw_affiliation_strings":["6National Medical Center, City of Hope, Duarte, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6National Medical Center, City of Hope, Duarte, CA","institution_ids":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080965667","display_name":"Kebede H. Begna","orcid":"https://orcid.org/0000-0003-2730-8593","observed_orcids":["https://orcid.org/0000-0003-2730-8593"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kebede Begna","raw_affiliation_strings":["7Division of Hematology, Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Division of Hematology, Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043655376","display_name":"Avyakta Kallam","orcid":"https://orcid.org/0000-0001-6801-1601","observed_orcids":["https://orcid.org/0000-0001-6801-1601","https://orcid.org/0009-0007-9323-4568"]},"institutions":[{"id":"https://openalex.org/I1307117695","display_name":"Nebraska Medical Center","ror":"https://ror.org/03azxga02","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1307117695"]},{"id":"https://openalex.org/I59130452","display_name":"University of Nebraska Medical Center","ror":"https://ror.org/00thqtb16","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I59130452"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Avyakta Kallam","raw_affiliation_strings":["8University of Nebraska Medical Center, Omaha, NE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8University of Nebraska Medical Center, Omaha, NE","institution_ids":["https://openalex.org/I1307117695","https://openalex.org/I59130452"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024732914","display_name":"Sameem M. Abedin","orcid":"https://orcid.org/0000-0003-1165-4766","observed_orcids":["https://orcid.org/0000-0003-1165-4766"]},"institutions":[{"id":"https://openalex.org/I204308271","display_name":"Medical College of Wisconsin","ror":"https://ror.org/00qqv6244","country_code":"US","type":"education","lineage":["https://openalex.org/I204308271"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sameem Abedin","raw_affiliation_strings":["9Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI","institution_ids":["https://openalex.org/I204308271"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070277385","display_name":"Rachel J. Cook","orcid":"https://orcid.org/0000-0001-7005-036X","observed_orcids":["https://orcid.org/0000-0001-7005-036X"]},"institutions":[{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rachel Cook","raw_affiliation_strings":["10Oregon Health and Science University, Portland, OR"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Oregon Health and Science University, Portland, OR","institution_ids":["https://openalex.org/I165690674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052380534","display_name":"Nathalie Javidi\u2010Sharifi","orcid":"https://orcid.org/0000-0003-0702-9837","observed_orcids":["https://orcid.org/0000-0003-0702-9837"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nathalie Javidi-Sharifi","raw_affiliation_strings":["11Dana-Farber Cancer Institute, Boston"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11Dana-Farber Cancer Institute, Boston","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Edward Dominguez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]},{"id":"https://openalex.org/I4210110459","display_name":"City of Hope","ror":"https://ror.org/01z1vct10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edward Dominguez","raw_affiliation_strings":["12Lymphoma Department, City of Hope, Duarte, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12Lymphoma Department, City of Hope, Duarte, CA","institution_ids":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Lu Miao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115926","display_name":"MEI Pharma (United States)","ror":"https://ror.org/02bgfrc80","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115926"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lu Miao","raw_affiliation_strings":["13MEI Pharma, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"13MEI Pharma, San Diego, CA","institution_ids":["https://openalex.org/I4210115926"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028729197","display_name":"Richard Ghalie","orcid":"https://orcid.org/0000-0001-6882-8179","observed_orcids":["https://orcid.org/0000-0001-6882-8179"]},"institutions":[{"id":"https://openalex.org/I4210115926","display_name":"MEI Pharma (United States)","ror":"https://ror.org/02bgfrc80","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115926"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard G Ghalie","raw_affiliation_strings":["13MEI Pharma, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"13MEI Pharma, San Diego, CA","institution_ids":["https://openalex.org/I4210115926"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5067633124","display_name":"Alexey Valeryevich Danilov","orcid":"https://orcid.org/0000-0003-4461-0970","observed_orcids":["https://orcid.org/0000-0003-4461-0970"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexey Danilov","raw_affiliation_strings":["14Department of Hematology and HCT, City of Hope National Medical Center, La Canada Flintridge, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"14Department of Hematology and HCT, City of Hope National Medical Center, La Canada Flintridge, CA","institution_ids":["https://openalex.org/I1301076528"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":15,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5000,"currency":"USD","value_usd":5000},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"142","issue":"Supplement 1","first_page":"4286","last_page":"4286"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.41990000009536743,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.41990000009536743,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.288100004196167,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.08229999989271164,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cdk9-inhibitor","display_name":"CDK9 inhibitor","score":0.9819999933242798},{"id":"https://openalex.org/keywords/relapsed-refractory-b-cell-lymphoma","display_name":"relapsed/refractory B-cell lymphoma","score":0.9440000057220459},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9700000286102295},{"id":"https://openalex.org/keywords/mcl-1","display_name":"Mcl-1","score":0.8769999742507935},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.8899999856948853},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.796999990940094},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.734000027179718},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8140000104904175},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.902999997138977},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.4880000054836273},{"id":"https://openalex.org/keywords/cardiotoxicity","display_name":"cardiotoxicity","score":0.4050000011920929},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.36000001430511475},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.4909999966621399},{"id":"https://openalex.org/keywords/mcl","display_name":"MCL","score":0.4410000145435333},{"id":"https://openalex.org/keywords/fl","display_name":"FL","score":0.5490000247955322},{"id":"https://openalex.org/keywords/venetoclax-resistance","display_name":"venetoclax resistance","score":0.4779999852180481}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7452231645584106},{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.6443929672241211},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5726933479309082},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5381143689155579},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.4793032705783844},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.475075900554657},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.46456778049468994},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.45297542214393616},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.44189009070396423},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4414829909801483},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.43520474433898926},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.4163970649242401},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4094454050064087},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3644733428955078},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.20131519436836243}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2023-179577","doi":"https://doi.org/10.1182/blood-2023-179577","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2023-179577","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8299999833106995}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2791038413","https://openalex.org/W4234339317","https://openalex.org/W3080900421","https://openalex.org/W4225091882","https://openalex.org/W3179857300","https://openalex.org/W2584413057","https://openalex.org/W3214672817","https://openalex.org/W4384199484","https://openalex.org/W4389467983","https://openalex.org/W2012639655"],"abstract_inverted_index":{"Background:":[0],"The":[1,156],"anti-apoptotic":[2],"protein":[3,52,568],"Mcl-1":[4,18,28,51,567,604],"contributes":[5],"to":[6,23,26,36,48,102,201,585,649,706],"the":[7,100,104,241,315,455,458,608,683,691],"pathophysiology":[8],"of":[9,114,178,341,358,391,412,492,521,566,579,592,603,614,621,638,710],"certain":[10],"B-cell":[11,126,232,291,680],"malignancies":[12,119],"and":[13,15,54,63,83,112,147,150,162,220,231,245,266,279,289,302,317,346,405,445,475,545,556,625,640,668,712],"AML,":[14,255],"dependence":[16],"on":[17,88,91,181,203,206,366,653,657],"is":[19,99,693],"associated":[20],"with":[21,56,79,124,214,386,424,482,497,507,588,664,679,689,699,703],"resistance":[22],"venetoclax.":[24],"Efforts":[25],"target":[27,331],"through":[29],"direct":[30],"inhibition":[31,709],"have":[32],"faced":[33],"challenges":[34],"due":[35],"cardiovascular":[37,501,670],"toxicities.":[38,671],"Voruciclib,":[39],"a":[40,92,159,175,182,207,323,356,389,416,513,577,658],"potent":[41],"oral":[42],"CDK9":[43],"inhibitor":[44],"(CDK9i),":[45],"was":[46,74,170,199,236,318,335,368,489,531,537,542,553,560,661,673],"shown":[47],"indirectly":[49],"downregulate":[50],"levels":[53],"synergize":[55],"venetoclax":[57,700],"in":[58,61,116,166,195,229,309,380,435,495,509,570,581,607,628,677,697,701],"preclinical":[59],"models":[60],"lymphoid":[62],"myeloid":[64],"malignancies.":[65,233,681],"In":[66,438,454],"solid":[67],"tumors,":[68],"voruciclib":[69,115,639,696],"maximum":[70],"tolerated":[71],"dose":[72,177,221,324,532],"(MTD)":[73],"defined":[75],"as":[76],"350":[77],"mg":[78,85,180,194,278,428,651],"continuous":[80],"daily":[81,172,202],"dosing,":[82],"600":[84],"when":[86],"used":[87],"days":[89,204,656],"1-14":[90,205],"21-day":[93],"cycle.":[94],"This":[95],"phase":[96],"1":[97,267],"study":[98,157,692],"first":[101],"evaluate":[103],"safety,":[105],"dose-limiting":[106],"toxicities":[107,688],"(DLT),":[108],"preliminary":[109],"efficacy,":[110],"pharmacokinetics,":[111],"pharmacodynamics":[113],"R/R":[117,704],"hematologic":[118],"(NCT03547115).":[120],"Methods:":[121],"Patients":[122],"(pts)":[123],"relapsed":[125],"NHL,":[127],"CLL,":[128,261],"or":[129],"AML":[130,196,230,288,387,483,508,523,617,630,705],"aged":[131],"\u226518":[132],"years":[133,337],"who":[134],"had":[135,348,355,388,401,402,415,429,484,526],"ECOG":[136,349],"performance":[137,350],"status":[138,351],"\u22641,":[139],"disease":[140],"progression":[141],"after":[142,636],"standard":[143],"therapies,":[144],"adequate":[145],"hepatic":[146],"renal":[148],"function,":[149],"no":[151,441,448,490,665,669,674],"prior":[152,215,360],"CDK9i":[153],"were":[154,164,190,218,252,343,378,443,447,462,503],"eligible.":[155],"followed":[158],"3+3":[160],"design":[161],"DLTs":[163,189,442,666],"assessed":[165,237],"Cycle":[167,436],"1.":[168,353],"Voruciclib":[169,529,645],"administered":[171,652],"continuously":[173],"at":[174,192,276,295,299,304,320,397,426,546,642,646],"starting":[176],"50":[179,277,427],"28-day":[183,208,659],"cycle":[184,209,660],"(Cohort":[185,210],"I).":[186],"After":[187],"2":[188,615],"observed":[191,444],"100":[193,280,296,398],"pts,":[197,273],"dosing":[198],"changed":[200],"II).":[211],"Also,":[212],"pts":[213,251,286,342,385,496,524,678,702],"allogeneic":[216,403],"transplant":[217,404],"excluded":[219],"escalation":[222,308],"(100,":[223],"150,":[224],"200":[225,305,321,518,547,650],"mg)":[226],"proceeded":[227],"separately":[228],"Disease":[234],"response":[235],"by":[238,573],"investigators":[239],"using":[240],"Lugano,":[242],"2008":[243],"iwCLL,":[244],"2017":[246],"ELN":[247],"criteria.":[248],"Results:":[249],"40":[250],"enrolled:":[253],"21":[254],"19":[256],"NHL":[257],"(9":[258],"DLBCL,":[259],"3":[260,262,264,359,394,419,431,486,593],"MCL,":[263],"FL":[265],"MZL).":[268],"Cohort":[269,282,310,381,439,510],"I":[270,382,511],"enrolled":[271,284],"16":[272],"8":[274],"each":[275],"mg.":[281,306],"II":[283,311],"24":[285,634],"(17":[287],"7":[290,298],"malignancies),":[292],"including":[293],"6":[294,600],"mg,":[297,301,322,519,548],"150":[300],"11":[303],"Dose":[307],"did":[312],"not":[313],"reach":[314],"MTD":[316],"stopped":[319],"that":[325],"achieved":[326,512],"plasma":[327],"concentrations":[328],"sufficient":[329],"for":[330],"inhibition.":[332],"Median":[333,364],"age":[334],"70":[336],"(range":[338,371],"40-90),":[339],"72.5%":[340],"\u226565":[344],"years,":[345],"77.5%":[347],"=":[352],"Pts":[354],"median":[357],"therapies":[361],"(range,":[362],"1-8).":[363],"duration":[365],"drug":[367],"5":[369,520],"weeks":[370],"1-22).":[372],"Drug-related":[373],"serious":[374],"adverse":[375],"events":[376],"(AEs)":[377],"reported":[379],"only.":[383],"Two":[384],"DLT":[390],"Grade":[392],"(Gr)":[393],"interstitial":[395],"pneumonitis":[396],"mg;":[399],"both":[400,632],"active":[406],"graft":[407],"versus":[408],"host":[409],"disease,":[410],"one":[411],"whom":[413],"also":[414],"concurrent":[417],"Gr":[418,430,450,485],"differentiation":[420],"syndrome.":[421],"One":[422,480,505],"pt":[423,481,506],"DLBCL":[425],"hypoxemic":[432],"respiratory":[433],"failure":[434],"4.":[437],"II,":[440],"there":[446],"non-hematologic":[449],"3-5":[451],"drug-related":[452,493],"AEs.":[453],"overall":[456],"population,":[457],"most":[459],"common":[460],"AEs":[461,502],"diarrhea":[463],"(30%),":[464],"nausea":[465],"(25%),":[466],"anemia":[467],"(22.5%),":[468,470],"fatigue":[469],"constipation":[471],"(17.5%),":[472],"dizziness":[473],"(15%)":[474,477],"dyspnea":[476],"[Table":[478],"1).":[479],"hyperbilirubinemia.":[487],"There":[488,672],"evidence":[491],"neutropenia":[494],"NHL.":[498],"No":[499],"significant":[500,675],"observed.":[504],"morphologic":[514],"leukemia-free":[515],"state.":[516],"At":[517],"10":[522],"(50%)":[525],"stable":[527],"disease.":[528],"pharmacokinetics":[530],"proportional,":[533],"mean":[534,539,557],"accumulation":[535],"ratio":[536],"2.4,":[538],"T":[540],"max":[541,552],"4":[543],"hours,":[544],"steady":[549],"state":[550],"C":[551,558],"925":[554],"ng/mL":[555,562],"trough":[559],"442":[561],"(~1":[563],"microM).":[564],"Analysis":[565],"expression":[569],"normal":[571],"lymphocytes":[572],"flow":[574],"cytometry":[575],"showed":[576],"trend":[578],"decrease":[580],"on-treatment":[582],"samples":[583,596,618],"compared":[584],"pre-treatment.":[586],"Consistent":[587],"this,":[589],"RNA-Seq":[590],"analysis":[591,613],"paired":[594],"CLL":[595],"confirmed":[597],"rapid":[598],"(after":[599],"hours)":[601],"downregulation":[602,620],"mRNA":[605],"transcript":[606],"malignant":[609],"B-cells.":[610],"Furthermore,":[611],"scRNA-Seq":[612],"longitudinal":[616],"demonstrated":[619],"MYC":[622],"transcriptional":[623],"program":[624],"oxidative":[626],"phosphorylation":[627],"circulating":[629],"blasts,":[631],"evident":[633],"hours":[635],"start":[637],"ongoing":[641],"C1D15.":[643],"Conclusions:":[644],"doses":[647],"up":[648],"14":[654],"consecutive":[655],"well":[662],"tolerated,":[663],"observed,":[667],"myelosuppression":[676],"As":[682],"safety":[684],"profile":[685],"suggested":[686],"non-overlapping":[687],"venetoclax,":[690],"now":[694],"evaluating":[695],"combination":[698],"exploit":[707],"dual":[708],"Bcl-2":[711],"Mcl-1.":[713]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2}],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2025-10-10T00:00:00"}